http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2337910-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcc7df8a0744f77b99c4e99a5d0eaf0a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04 |
| filingDate | 2003-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95d7e954a236fe017fa3d1d505cf6880 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee987b7c7e6fea379c3f345292140e29 |
| publicationDate | 2008-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2337910-C2 |
| titleOfInvention | Derivatives of substituted dihydropyranoindole-3,4-dione as inhibitors of plasminogene activator inhibitor-1 (pai-1) |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to substituted of dihydropyranoindole-3,4-dione of formula I and formula II: where X stands for H, R 1 stands for H, phenyl, benzyl, cycles of said phenyl and benzyl can be substituted with 1-3 substituents, selected independently on each other from group, which includes halogen, C 1 -C 6 -alkyl, C 1 -C 6 -perfluoroalkyl, -O-C 1 -C 6 -perfluoroalkyl, C 1 -C 6 -alkoxygroup; where R 2 stands for H, -OH; R3 stands for H, phenyl, benzyl, benzyloxygroup, cycles of these groups can be optionally substituted with 1-3 substituents, selected independently on each other from group including phenyl, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -perfluoroalkyl, -O-C 1 -C 6 -perfluoroalkyl, C 1 -C 6 -alkoxygroup, pharmaceutically acceptable salts of said compounds. Compounds demonstrate activity of inhibiting plasminogene activator inhibitor (PAI-1), which allows using them for production of medication for treatment of pathological states resulting from fibrinolytic disorders. n EFFECT: obtaining compounds, demonstrating activity in inhibiting plasminogene activator inhibitor which allows using them in pharmacology. n 23 cl, 1 dwg, 1 tbl, 13 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2675240-C1 |
| priorityDate | 2002-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 256.